Adequate evidence was also found suggesting that the harms of screening may be substantial in some cases, including unnecessary surgery in women without cancer. Based on these findings, the USPSTF concludes with moderate certainty that the harms of ovarian cancer screening outweigh the potential benefits.
Hyperthermic intraperitoneal chemotherapy with surgery increases survival for epithelial ovarian cancer patients
Patients with stage 3 epithelial ovarian cancer treated with hyperthermic intraperitoneal chemotherapy (HIPEC) in addition to cytoreductive surgery and neoadjuvant chemotherapy experienced increased overall and recurrence-free survival.
BRCA1 promoter methylation in normal white blood cells (WBCs) was linked to risk for high-grade serous ovarian cancer (HGSOC).
The researchers found that 89 and 81% of patients who underwent cytoreductive surgery without HIPEC and with HIPEC, respectively, had events of disease recurrence or death in the intention-to-treat analysis (hazard ratio, 0.66).
Only patients with HGSOC had elevated methylation (9.6%; odds ratio, 2.91), in contrast to 5.1 and 4.0% of patients with non-serous ovarian cancer and low-grade serous ovarian cancer (LGSOC), respectively.
The researchers found that 15 of the 32 evaluable patients at the 6-month time point had complex atypical hyperplasia (47%), 9 had G1 endometrial cancer (28%), and 8 had grade 2 endometrial cancer (25%).
Regardless of the cytology result, 5-year ≥CIN3 risks for an HPV-negative co-test nearly matched the performance of a negative co-test for each successive round of screening (0.114, 0.061, and 0041%, respectively).
The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.
For women aged 21 to 29 years, the USPSTF recommends screening for cervical cancer with cervical cytology alone every 3 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone or every 5 years with hrHPV testing alone (A recommendation).
Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.
6% didn't first learn about it from their obstetrician-gynecologist; nearly three-quarters (73%) of women who knew about the treatment first heard about it from someone other than their obstetrician-gynecologist.
The approvals were based on two, placebo-controlled trials (SOLO-2, Study 19) in patients with recurrent ovarian cancers who were in response to platinum-based therapy.
The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.
Leiomyomas, age younger than 35 years, at least 2 prior cesarean deliveries, and history of sterilization were factors that predisposed patients to post-ablation hysterectomy.
For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.
Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.
Zejula is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial.
The researchers found that disease-free survival was 81.3 and 81.6% in the TAH and TLH groups, respectively, at 4.5 years of follow-up.
The approval is supported by a randomized trial (n=533) of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received ≥2 prior treatments of platinum-based chemotherapy and were in a complete or partial response to the most recent treatment.
Study authors identified a total of 8,545 patients undergoing 73,577 administrations of chemotherapy with minimal or low emetic risk.
After the second weekly cisplatin infusion, significant magnesium wasting was observed, regardless of whether furosemide or mannitol was used.
The clinical practice guideline is the first for primary prevention of cervical cancer that is adapted to various areas in the world with different levels of socio-economic and structural resource settings.
Coffee consumption speeds the time to bowel movement after complete staging surgery of gynecologic cancers, according to a study published in the February issue of the American Journal of Obstetrics & Gynecology.
The Food and Drug Administration (FDA) has granted accelerated approval for Rubraca (rucaparib; Clovis Oncology) for the treatment of advanced ovarian cancer in women have been treated with two or more chemotherapies and whose tumors have deleterious BRCA mutation as identified by an FDA-approved companion diagnostic test.